Molecular Biology of the Cell Call for Nominations: MBC Editor-in-Chief

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Originally published as MBC in Press, 10.1091/mbc.E03-12-0873 on February 6, 2004

Vol. 15, Issue 4, 1600-1608, April 2004

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
E03-12-0873v1
15/4/1600    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wittenmayer, N.
Right arrow Articles by Jockusch, B. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wittenmayer, N.
Right arrow Articles by Jockusch, B. M.

Tumor Suppressor Activity of Profilin Requires a Functional Actin Binding Site

Nina Wittenmayer *, Burkhard Jandrig {dagger}, Martin Rothkegel *, Kathrin Schlüter * {ddagger}, Wolfgang Arnold §, Wolfgang Haensch ||, Siegfried Scherneck {dagger}, and Brigitte M. Jockusch * ¶

* Cell Biology, Zoological Institute, Technical University of Braunschweig, D-38092 Braunschweig, Germany; {dagger} Tumor Genetics, Max-Delbrück-Center for Molecular Medicine, D-13092 Berlin-Buch, Germany; § atugen AG, D-13125 Berlin-Buch, Germany; and || Clinic of Surgery and Surgical Oncology, Robert Rössle Hospital, D-13122 Berlin-Buch, Germany

Submitted December 5, 2003; Revised January 7, 2004; Accepted January 8, 2004
Monitoring Editor: Thomas Pollard

Profilin 1 (PFN1) is a regulator of the microfilament system and is involved in various signaling pathways. It interacts with many cytoplasmic and nuclear ligands. The importance of PFN1 for human tissue differentiation has been demonstrated by the findings that human cancer cells, expressing conspicuously low PFN1 levels, adopt a nontumorigenic phenotype upon raising their PFN1 level. In the present study, we characterize the ligand binding site crucial for profilin's tumor suppressor activity. Starting with CAL51, a human breast cancer cell line highly tumorigenic in nude mice, we established stable clones that express PFN1 mutants differentially defective in ligand binding. Clones expressing PFN1 mutants with reduced binding to either poly-proline-stretch ligands or phosphatidyl-inositol-4,5-bisphosphate, but with a functional actin binding site, were normal in growth, adhesion, and anchorage dependence, with only a weak tendency to elicit tumors in nude mice, similar to controls expressing wild-type PFN1. In contrast, clones expressing a mutant with severely reduced capacity to bind actin still behaved like the parental CAL51 and were highly tumorigenic. We conclude that the actin binding site on profilin is instrumental for normal differentiation of human epithelia and the tumor suppressor function of PFN1.


Article published online ahead of print. Mol. Biol. Cell 10.1091/mbc.E03–12–0873. Article and publication date are available at www.molbiolcell.org/cgi/doi/10.1091/mbc.E03–12–0873.

Abbreviations used: Arp, actin-related protein; PFN1, profilin 1; PIP2; phospho-inositol-4,5-bisphosphate.

{ddagger} Present address: BD Biosciences, D-69126 Heidelberg, Germany.

Corresponding author. E-mail address: bmj{at}tu-bs.de.




This article has been cited by other articles:


Home page
Mol. Cell. Biol.Home page
J. Shao, W. J. Welch, N. A. DiProspero, and M. I. Diamond
Phosphorylation of Profilin by ROCK1 Regulates Polyglutamine Aggregation
Mol. Cell. Biol., September 1, 2008; 28(17): 5196 - 5208.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Copyright © 2004 by The American Society for Cell Biology. Terms of copyright protection, warranties, and disclaimers.